Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper

Baxter Pays $24 Million To Bring JV In-house

publication date: Jan 30, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Baxter International will take its Shanghai Baxter JV completely in-house by buying the 40% stake in the JV that had been owned by Worldbest Treeful Pharmaceutical. Worldbest is in financial trouble, and the Bank of China ordered the JV stake to be put up for auction. Worldbest Treeful originally invested $4.8 million for a 40% participation in the venture. Baxter paid 180 million RMB, about $24.3 million, to acquire the position. More details...

Stock Symbol: (NYSE: BAX) 




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Other Events

China Pharmaceutical R&D Summit
April 23-26, 2012
Shanghai, China


Biosimilars Asia 2012
April 23-26, 2012
Shanghai, China


Vaccines China 2012
April 23-26, 2012
Shanghai, China

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners